TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03978468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interagency Collaboration (ICollab)
Description: The intervention has the following components: 1) ICollab Component 1: The Nurse Clinician will review clinic and emergency room (ER) visit notes for clinicians' recommendations and communicate these to the home health nurse (HHN). 2) ICollab Component 2a: The intervention team will meet weekly by phone with HHNs (6 times/ child). The Nurse Clinician will document meeting notes for each child in the ER, communicate this information with the HHN, and share it with the primary care provider (PCP) by routing the note through the ER or faxing the note. 3) ICollab Component 2b: The Nurse Clinician will be available as a resource for the HHN during regular work hours for clinical problem-solving. 4) ICollab Component 2c: the intervention team physician will offer her contact information for clinical problem-solving about the child to the PCP. The Nurse Clinician will communicate with the PCP about the plan developed in the meetings, and changes to plan of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare \& Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare \& Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.
Study: NCT03008018

Intervention type: DRUG
Group type: OTHER
Intervention: KA2507
Description: KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
Study: NCT04347499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CaCBT based guided self help using Khushi aur Khatoon Manual
Description: CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
Study: NCT04261855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Description: Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lutetium-177 (177Lu)-DOTATATE
Description: Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart
Study: NCT03092713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)
Description: The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The Control Group receives usual assessment and treatment at Oslo University Hospital.
Study: NCT04351113

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MITO-AO
Description: Participants will receive 160 mg with breakfast on day 1 of bed rest and 40 mg with breakfast on days 2-5.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PB-125
Description: Participants will receive 100 mg on days 1-5 of bed rest.
Study: NCT04569786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via IM injection.
Study: NCT01891812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 50%
Study: NCT01253928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 45mg qd for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: 45mg qd for 4 months
Study: NCT03788915

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online dietetic lifestyle counseling
Description: The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
Study: NCT04022824

Intervention type: OTHER
Intervention: OSA
Description: Patients with OSA (apnea hypopnea index ≥15) based on sleep study

Intervention type: OTHER
Intervention: Non-OSA
Description: Patients without OSA (apnea hypopnea index \<15) based on sleep study
Study: NCT02605213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin for treatment of primary sclerosing cholangitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for control Group of primary sclerosing vhlangitis
Study: NCT03321994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stereotaxic unit, navigation
Description: CT-guided needle guidance using stereotaxic unit, navigation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional biopsy technique
Description: CT-guided needle guidance using conventional biopsy technique
Study: NCT01682148

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study: NCT03265184

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green coffee extract
Description: Patients in treatment group take 400 mg GCE supplements twice a day for tow month
Study: NCT03014167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: All eligible individuals will receive a single dose of 400 mg albendazole.
Study: NCT03265184

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: green coffee extract
Description: Patients in treatment group take 400 mg GCE supplements twice a day for tow month
Study: NCT03014167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: All eligible individuals will receive a single dose of 400 mg albendazole.
Study: NCT01058850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rindopepimut
Description: 250 or 500 mcg; intradermal injection
Study: NCT00003525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02987738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: two administrations in the evening and 12 hours later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: two administrations in the evening and 12 hours later
Study: NCT04026152

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
Study: NCT00678587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: 75 mg, once daily, oral
Study: NCT04543851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARA - carbon fibre adjustable re-usable accessory for breast positioning
Description: Breast positioning to alleviate infra-mammary fold and lateral breast sag
Study: NCT00678587

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, once daily, oral
Study: NCT05837078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ridge splitting with implant placement
Description: ridge splitting of mandibular denture followed by two implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ridge splitting with implant placement
Description: ridge splitting of mandibular denture followed by two implant placement
Study: NCT01975779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A1: Lu AE58054 or placebo
Description: One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
Study: NCT06749171

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: ONCAB (on-pump coronary artery bypass grafting), OPCAB (off-pump coronary artery bypass grafting), NTA (no-touch aorta technique), MICSCAB (minimally invasive multiple coronary artery bypass grafting)

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: ONCAB (on-pump coronary artery bypass grafting), OPCAB (off-pump coronary artery bypass grafting), NTA (no-touch aorta technique), MICSCAB (minimally invasive multiple coronary artery bypass grafting)
Study: NCT02561962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.
Study: NCT04351113

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo on days 1-5 of bed rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Leg Movement (PLM)
Description: Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Leg Movement (PLM)
Description: Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Leg Movement (PLM)
Description: Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar flexion
Description: Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar flexion
Description: Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plantar flexion
Description: Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric knee extensor test
Description: Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric knee extensor test
Description: Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isometric knee extensor test
Description: Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Participants will undergo 5 days bed rest after 5 day baseline assessments
Study: NCT01975779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A2: Lu AE58054 or placebo
Description: One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B1: Lu AE58054
Description: Two single oral doses 60 mg with \>=7 days washout.
Study: NCT02167841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knee-Chest Position
Study: NCT04351113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Participants will undergo 5 days bed rest after 5 day baseline assessments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bed rest
Description: Participants will undergo 5 days bed rest after 5 day baseline assessments
Study: NCT00995150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG20
Description: levonorgestrel-releasing intrauterine system for contraception

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG20
Description: levonorgestrel-releasing intrauterine system for contraception

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Description: Mirena intrauterine system
Study: NCT01291563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 1 capsule of moxifloxacin (400 mg/capsule) on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: 8 tablets of TMC207 (100 mg/tablet) on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TMC207 placebo
Description: 8 tablets of TMC207 placebo on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: 1 capsule of moxifloxacin placebo on Day 2
Study: NCT03289611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sFlt-1 / PlGF ratio
Description: * Ambulatory management if sFlt-1 / PlGF ratio is below 38~* usual management if sFlt-1/PlGF is between 38 and 85.~* If the ratio is \> 85, monitoring will be intensified and patient hospitalization will be continued
Study: NCT04415086

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: convalescent plasma
Description: The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: convalescent plasma
Description: The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: convalescent plasma
Description: The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
Study: NCT01551433

Intervention type: DEVICE
Intervention: wireless pulse oximeter (Wipox)
Description: In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
Study: NCT02398565

Intervention type: OTHER
Intervention: No intervention
Study: NCT00005772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Induced hypothermia
Description: Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group: standard care
Study: NCT00043082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: intravenous q 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: intravenous q 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: intravenous q 4 weeks
Study: NCT00891176

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenitorixTM
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenitorixTM
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
Study: NCT02561962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.